Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment
- PMID:21762356
- DOI: 10.1111/j.1478-3231.2011.02593.x
Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment
Abstract
Background: Hepatitis delta is caused by infection with the hepatitis D virus (HDV) and is considered the most severe form of viral hepatitis. Treatment options for hepatitis delta are limited, with only 25% of patients responding to interferon (IFN)-alfa-based therapies. The role of the adaptive immune system in controlling HDV infection during spontaneous or treatment-induced viral clearance is not well understood.
Methods: We studied HDV-specific cytokine production of peripheral blood mononuclear cells stimulated with HDV peptide pools as well as serum cytokine levels in well-characterized patients with chronic HDV infection before and during pegylated-interferon-alfa±adefovir therapy.
Results: Hepatitis D virus-specific interleukin (IL)-2, IFN-γ-, interferon-inducible protein-10 and IL-10-responses were detectable in 53%, 35%, 65% and 6% of hepatitis delta patients. HDV-specific IFN-γ responses tended to be more common in patients with low HDV viral loads. HDV-specific cytokine responses declined during pegylated (PEG)-IFNa therapy and patterns of changes were associated with the treatment response. Serum cytokine levels also showed distinct changes during PEG-IFNa treatment.
Conclusion: We suggest that cellular HDV-specific immune responses contribute to the control of HDV infection and that cytokine responses may indicate response to type-I-IFN-based antiviral therapy of hepatitis delta.
© 2011 John Wiley & Sons A/S.
Similar articles
- Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, Dalekos GN, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C.Keskin O, et al.Clin Gastroenterol Hepatol. 2015 Dec;13(13):2342-49.e1-2. doi: 10.1016/j.cgh.2015.05.029. Epub 2015 Jun 1.Clin Gastroenterol Hepatol. 2015.PMID:26044319Clinical Trial.
- Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.Lutterkort GL, Wranke A, Hengst J, Yurdaydin C, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Manns MP, Dienes HP, Falk C, Wedemeyer H, Heidrich B.Lutterkort GL, et al.J Viral Hepat. 2018 Nov;25(11):1384-1394. doi: 10.1111/jvh.12947. Epub 2018 Jul 10.J Viral Hepat. 2018.PMID:29888837
- Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group.Heidrich B, et al.Hepatology. 2014 Jul;60(1):87-97. doi: 10.1002/hep.27102.Hepatology. 2014.PMID:24585488
- Treatment of delta hepatitis.Gunsar F.Gunsar F.Expert Rev Anti Infect Ther. 2013 May;11(5):489-98. doi: 10.1586/eri.13.35.Expert Rev Anti Infect Ther. 2013.PMID:23627855Review.
- Current management of delta hepatitis.Rizzetto M.Rizzetto M.Liver Int. 2013 Feb;33 Suppl 1:195-7. doi: 10.1111/liv.12058.Liver Int. 2013.PMID:23286865Review.
Cited by
- Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus.Usai C, Gill US, Riddell AC, Asselah T, Kennedy PT.Usai C, et al.Aliment Pharmacol Ther. 2022 Apr;55(8):978-993. doi: 10.1111/apt.16807. Epub 2022 Mar 16.Aliment Pharmacol Ther. 2022.PMID:35292991Free PMC article.Review.
- Hepatitis D Virus: A Call to Screening.Ahn J, Gish RG.Ahn J, et al.Gastroenterol Hepatol (N Y). 2014 Oct;10(10):647-86.Gastroenterol Hepatol (N Y). 2014.PMID:27540336Free PMC article.
- Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery.Noureddin M, Gish R.Noureddin M, et al.Curr Gastroenterol Rep. 2014 Jan;16(1):365. doi: 10.1007/s11894-013-0365-x.Curr Gastroenterol Rep. 2014.PMID:24293018Free PMC article.Review.
- TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection.Usai C, Maestro S, Camps G, Olague C, Suárez-Amaran L, Vales A, Aragon T, Hommel M, Aldabe R, Gonzalez-Aseguinolaza G.Usai C, et al.JHEP Rep. 2020 Mar 10;2(3):100098. doi: 10.1016/j.jhepr.2020.100098. eCollection 2020 Jun.JHEP Rep. 2020.PMID:32382723Free PMC article.
- Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, Strauss O, Zimmer CL, Berglin L, Schirdewahn T, Ciesek S, Marquardt N, von Hahn T, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Sandberg JK, Björkström NK.Dias J, et al.J Hepatol. 2019 Aug;71(2):301-312. doi: 10.1016/j.jhep.2019.04.009. Epub 2019 May 14.J Hepatol. 2019.PMID:31100314Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources